The Total addressable market is $30Bn (based on branded drugs current prices) The split of the same by molecule is available in their A/Rs and in the post by Bina on this thread. Please read the entire thread before posting questions, that will help avoid duplication.
As for the spin off & what the market reaction to it - Your guess is as good as mine, I don’t see the point in speculating about it. It would probably be a better use of our time to focus on the business. As for the IPO, Dr Mithun pointed out earlier that during the Syngene spin off, Biocon shareholders got a preferential allotment during the IPO. So I don’t understand why Nikhil thinks this will be a “disaster” for existing share holders. Just apply for the Biologics IPO if thats what interests you.